House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The House Appropriations Committee July 10 voted 31-25 to approve legislation that would provide $185.8 billion in funding for the departments of Labor, Health…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Headline
The AHA June 13 released an infographic highlighting the many ways hospitals and health systems advance health and support their communities. Among other…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
The AHA praised House and Senate leaders in letters June 12 for reintroducing the Improving Seniors’ Timely Access to Care Act, bipartisan legislation that…